Heidelberg, Germany, March 23, 2017 - Affimed N.V. (Nasdaq: AFMD) today announced that on March 30, 2017, the Company will release its financial results for the quarter and year ended December 31, 2016. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Thursday, March 30, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 9811704.
|Local - Amsterdam, the Netherlands:||+31 (0) 20 721 9158|
|Local - Copenhagen, Denmark:||+45 32 71 16 60|
|Local - Frankfurt, Germany:||+49 (0) 69 2222 10626|
|Local - Geneva, Switzerland:||+41 (0) 22 417 7109|
|Local - London, U.K.:||+44 (0) 20 3427 1911|
|Local - New York City, U.S.A.:||+1 646 254 3361|
|Local - Paris, France:||+33 (0) 1 76 77 22 22|
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341